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CML was diagnosed in the beginning of 1980, following incidental discovery of gnanubocytosis without other symptoms. The patient reacted favorably to repeated courses of busulfan. In February 1987 a steady increase of myeboblasts in the peripheral blood was seen, followed within a month by a full blown myeboblastic crisis. Among other drugs treatment with alpha-2-intenferon had no success. The patient died 2 months later.
MATERIALS AND METHODS

Samples.
Bone marrow aspirates and blood samples were sent to Rotterdam for molecular investigations. The samples were sterile and hepaninized and reached the laboratory within 24 hours after aspiration.
All sampling was part ofdiagnostic and clinical follow-up procedures and obtained only after informed consent of the patients. The following probes were used in Southern blot analysis and in situ hybridization2: -bcr. 3'-bcr, c-sis, and c-abl only.
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